Walvax Biotechnology Co., Ltd. (300142.SZ)

12.90 +0.01 (+0.08%) At close: 03:04PM CST

Walvax Biotechnology Co., Ltd.

No. 395 Kexin Road
Wuhua District
Kunming 650101
China
86 87 1683 30860
https://www.walvax.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 2,388

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Runsheng Jiang	Director & President	N/A	N/A	1957
Ms. Hua Zhou	Chief Financial Officer	N/A	N/A	1967
Ms. Yun Yan Wu	Director of Operations	N/A	N/A	1982
Mr. Jin Long Zhao	Chief Investment Officer	N/A	N/A	1973
Ms. Lin Yuan	Technical Director	N/A	N/A	1982
Mr. Wei Yao	Marketing Director	N/A	N/A	1972
Mr. Qing Gongsun	Director of Human Resources	N/A	N/A	1966
Mr. Jiankang Zhang	VP & Director	N/A	N/A	1957
Mr. Shao Zhong Dong	VP & Director	N/A	N/A	1968
Mr. Yu Ran Liu	Board Secretary	N/A	N/A	1989

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.

Description

Walvax Biotechnology Co., Ltd., researches, develops, produces, and markets vaccines in China. The company offers SARS-CoV-2 mRNA vaccine, an immunization to prevent COVID-19 to individuals 18 years of age and older; 13-valent pneumococcal polysaccharide conjugate vaccine, an invasive diseases caused by streptococcus pneumoniae for use in infants and children 6 weeks through 5 years of age; and recombinant human papillomavirus bivalent vaccine, for the prevention of cervical cancers and precancerous lesions caused by human; 23-valent pneumococcal polysaccharide vaccine, for individuals age 2 years of pneumococcal diseases; ACYW135 meningococcal polysaccharide vaccine, for the prevention of invasive meningococcal diseases; Group A and C meningococcal polysaccharide vaccine, for in adults and children over the age of 2 years and adults to prevent disease caused by the bacterium neisseria meningitidis; Group A and Group C meningococcal conjugate vaccine, for the prevention of invasive meningococcal diseases caused by Neisseria meningitidis serogroups A and C for children 3 months through 5 years of age. It also provides haemophilus influenzae type b conjugate vaccine, for the prevention of invasive infections for children 2 months through 5 years of age; diphtheria, tetanus, and acellular pertussis combined vaccine, for diphtheria and tetanus for infants and children 3 months through 6 years of age. Walvax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Kunming, China.

Corporate governance

Walvax Biotechnology Co., Ltd.’s ISS governance QualityScore as of 1 June 2024 is 2. The pillar scores are Audit: 5; Board: 2; Shareholder rights: 1; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.